Event

The value of medical innovation varies depending on the stakeholder perspective and decision context. Regulatory authorities primarily focus on clinical value, while coverage, pricing, and reimbursement decisions often incorporate economic criteria and, in some settings, broader societal considerations. Explore the value assessment of innovative drugs from the perspectives of relevant stakeholders, their respective data requirements, and their methods and processes with a focus on orphan drugs and advanced therapy medical products.

Technical Topics Include:

• Stakeholder perspectives on value, including regulators, payers, investors, patients, and clinicians
• Clinical, economic, and societal criteria used in value assessment
• Value-based pricing concepts and national payer perspectives
• Methods for value assessment, including ICERs, comparative effectiveness research, and relative effectiveness
• Multicriteria decision analysis (MCDA) and broader value frameworks
• Applications in orphan drugs, advanced therapy medicinal products, and traditional innovative medicines

This Course Includes Tools and Concepts That Can Be Immediately Applied, Including:

• Practical examples of value assessment across decision contexts
• Comparison of narrow and holistic approaches to value-based pricing
• Case illustrations spanning rare diseases, cell-gene therapy, and broader indications
• Frameworks to support transparent and consistent value assessment

Participants will gain a structured understanding of how value is defined, measured, and applied across stakeholders to support pricing, reimbursement, and policy decisions for innovative medicines.

Familiarity with health economic evaluation is desirable, but the course assumes little or no familiarity with economic valuation theory.

Schedule:

LENGTH: 4 Hours | Course runs 1 day

Sunday, 17 May 2026 | Course runs 1 Day